Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors

• Published in: Frontiers in immunology Vol. 13; p. 1024755
• Main Authors: Ma, Yu-Xiang, Liu, Fu-Rong, Zhang, Yang, Chen, Qun, Chen, Zhi-Qiang, Liu, Qian-Wen, Huang, Yan, Yang, Yun-Peng, Fang, Wen-Feng, Xi, Ning, Kang, Ning, Zhuang, Yu-Lei, Zhang, Qi, Jiang, Ying-Zhi, Zhang, Li, Zhao, Hong-Yun
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 20.10.2022
• Subjects: Administration, Oral; Adult; AXL; c-Mer Tyrosine Kinase; Humans; Immunology; Maximum Tolerated Dose; MET; Neoplasms - pathology; phase I; preclinical; Protein Kinase Inhibitors - therapeutic use; tyrosine kinase inhibitor; VEGFR2; VEGFR2; phase I; tyrosine kinase inhibitor; AXL; preclinical; MET

CT053PTSA is a novel tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, FLT3 and MERTK. Here, we present preclinical data about CT053PTSA, and we conducted the first-in-human (FIH) study to evaluate the use of CT053PTSA in adult patients with pretreated advanced solid tumors. The selectivity a...